Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maesen, F.
Right arrow Articles by Zweers, P.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Maesen, F.
Right arrow Articles by Zweers, P.

Chest, Vol 97, 590-594, Copyright © 1990 by American College of Chest Physicians

ARTICLES

Bronchodilator effect of inhaled formoterol vs salbutamol over 12 hours

FP Maesen, JJ Smeets, HL Gubbelmans and PG Zweers
Department of Pulmonary Diseases, De Wever Hospital, Heerlen, The Netherlands.

The bronchodilator effects were compared in 16 stable asthma patients for 12 hours after either 12 micrograms formoterol or 200 micrograms salbutamol from a metered-dose aerosol in a randomized, double-blind, crossover study. The FEV1 measured before 1, 2, 4, 6, 8, 10 and 12 hours after administration was used as the parameter. From 2 hours onwards after dosage, the bronchodilator effect of formoterol was statistically significantly greater than that of salbutamol. The effect of formoterol lasted longer, and even after 12 hours, the FEV1 was still 20 percent above the baseline value. This is clinically significant and offers new possibilities for treatment of the so-called "morning dip." Both agents were well tolerated.


This article has been cited by other articles:


Home page
 ChestHome page
S. G. M. Cloosterman, I. D. Bijl-Hofland, C. L. A. van Herwaarden, R. P. Akkermans, F. J. J. van den Elshout, H. T. M. Folgering, and C. P. van Schayck
A Placebo-Controlled Clinical Trial of Regular Monotherapy With Short-Acting and Long-Acting {beta}2-Agonists in Allergic Asthmatic Patients
Chest, May 1, 2001; 119(5): 1306 - 1315.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. PALMQVIST, T. IBSEN, A. MELLÉN, and J. LÖTVALL
Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients
Am. J. Respir. Crit. Care Med., July 1, 1999; 160(1): 244 - 249.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American College of Chest Physicians.